BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 21, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Australia advances infrastructure investments in diabetes, cardiovascular, regenerative therapies
To read the full story,
subscribe
or
sign in
.
Australia advances infrastructure investments in diabetes, cardiovascular, regenerative therapies
Jan. 12, 2021
By
Tamra Sami
PERTH, Australia – Australia’s Medical Technologies and Pharmaceuticals Industry Growth Center (MTPConnect) is boosting funding for the translation and commercialization of research in diabetes, cardiovascular disease and regenerative medicine.
BioWorld
BioWorld Asia
Cardiovascular
Diabetes
Asia-Pacific
Australia